Price Chart

Profile

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
URL https://www.grifols.com
Investor Relations URL https://www.grifols.com/en/presentations-and-events
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 28, 2025 (est.)
Last Earnings Release Jul. 30, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Jun. 03, 2021

Profile

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
URL https://www.grifols.com
Investor Relations URL https://www.grifols.com/en/presentations-and-events
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 28, 2025 (est.)
Last Earnings Release Jul. 30, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Jun. 03, 2021